A randomized, blinded, phase IIb trial of telbivudine (LdT) versus the combination of telbivudine and valtorcitabine (Val-LdC) in patients with chronic hepatitis B.

Trial Profile

A randomized, blinded, phase IIb trial of telbivudine (LdT) versus the combination of telbivudine and valtorcitabine (Val-LdC) in patients with chronic hepatitis B.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Valtorcitabine (Primary) ; Telbivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Idenix Pharmaceuticals
  • Most Recent Events

    • 15 Dec 2009 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov record.
    • 15 Dec 2009 Actual initiation date (1 May 2005) and planned number of patients (130) added as reported by ClinicalTrials.gov record.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top